$CAPR Stock Notification: Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28

Bleichmar Fonti & Auld LLP announced a securities fraud class action against Capricor Therapeutics and certain senior executives, with a lead plaintiff deadline of September 28, 2026. The suit alleges Capricor made false statements about Deramiocel and its clinical data, including undisclosed post-hoc changes to its statistical analysis plan before the BLA resubmission. CAPR fell 64.5% on July 27, 2026 after FDA briefing documents raised concerns, and another 36% after an advisory committee voted 9-3 that evidence did not support Deramiocel's efficacy.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.